Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05420454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study for the Neoadjuvant Treatment of Breast Cancer

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University to Second Affiliated Hospital, Zhejiang University, School of Medicine
  2. Start date: Jun 10, 2022 to Jul 10, 2022
    • Interventions: Albumin-Bound Paclitaxel,Carboplatin，Trastuzumab，Pertuzumab (Drug), Albumin-Bound Paclitaxel,Epirubicin, cyclophosphamide (Drug)… to Carboplatin (Drug), Cyclophosphamide (Drug), Cyclophosphamide (Drug), Docetaxel (Drug), Docetaxel (Drug), Epirubicin (Drug), Epirubicin…
    • Study description shortened, about 54 words
    • Study title shortened, about 9 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Due to the unique advantages of albumin-bound paclitaxel, several studies in China and abroad have tried to use albumin-bound paclitaxel for neoadjuvant treatment of breast cancer up to now. However, comparative studies between paclitaxel and docetaxel are still rare, In this study, a prospective, randomized, open-label, multi-center clinical study was conducted to analyse the efficacy and safety of albumin-bound paclitaxel and docetaxel in the neoadjuvant treatment of breast cancer, and to further analyse the efficacy and safety of albumin paclitaxel in combination with chemotherapy for postoperative breast cancer in different subtypes of breast cancer patients, in order to obtain more realistic data and provide new treatment options for breast cancer patients.
Trial Details
NCT Number NCT05420454
Lead Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 1,576 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov